Human Pharma

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus Overall R&D investment up 7% to 3.7 billion EUR in 2020…

Read More »